MCMilda Chmieliauskaite

Milda Chmieliauskaite

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Milda Chmieliauskaite has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Arwa Mohammad Farag

    Department of Oral Diagnostic Sciences, Faculty of Dentistry King Abdul Aziz University Jeddah Saudi Arabia

    3 shared publications
  • Gary D. Klasser

    Department of Diagnostic Sciences, School of Dentistry Louisiana State University Health Sciences Center New Orleans Louisiana USA

    3 shared publications
  • Rui Albuquerque

    Oral Medicine, Guy's & St. Thomas' NHS Foundation Trust (GSTT), Guy's Hospital; Faculty of Dentistry, Oral & Craniofacial Sciences King's College London London UK

    3 shared publications
  • Andrea Sardella

    Department of Biomedical, Surgical and Dental Sciences, Unit of Oral Medicine, Oral Pathology and Gerodontology, University of Milan, Milan, Italy

    2 shared publications
  • Andrea Sardella

    Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy

    2 shared publications
  • Anura Ariyawardana

    College of Medicine and Dentistry, James Cook University, Cairns, Queensland, Australia

    2 shared publications

Latest Publications

  • Open Access

    Family Impact of Burning Mouth Syndrome: A Cross‐Sectional Study Using FROM ‐16

    by Mona Jullie Hajj, Nicholas Sotak, Alessandro Villa, Alan Roger Santos‐Silva, Lloyd Mancl, Thaís Cristina Esteves‐Pereira, Milda Chmieliauskaite

    Background: Burning mouth syndrome (BMS) is a chronic oral pain condition associated with psychological distress and reduced quality of life. Although BMS' impact on patients is documented, family member impact remains poorly understood. This study evaluated family impact using Family Reported Outcome Measure (FROM‐16), explored family burden associations, assessed FROM‐16 domains, and identified unmet support needs. Methods: This cross‐sectional study included 26 patient–family member dyads from an oral medicine clinic. Family burden was assessed using FROM‐16. Open‐ended responses were analyzed thematically to characterize family experiences and support needs. Associations between family burden and demographic/clinical variables were explored using nonparametric analyses. Results: Median total FROM‐16 score was 5.5. Emotional burden exceeded personal/social burden, with worry, sadness, and frustration most common. Disruptions in family activities, eating habits, and family expenses were main social concerns. Lower household income was associated with higher burden scores. Qualitative findings confirmed emotional strain, altered social behaviors, and financial stress. Knowledgeable healthcare providers were the primary support source, although unmet healthcare, mental health, social, and treatment needs persisted. Conclusions: BMS affects families through emotional distress, disrupted eating habits, and social activities. These preliminary findings support evaluation of family‐centered multidisciplinary approaches to improve support for patients and families.

  • WWOM VII: Effectiveness of topical interventions in the management of burning mouth syndrome: A systematic review

    by Sandra Goncalves, Barbara Carey, Arwa M. Farag, Michal Kuten‐Shorrer, Zuhair S. Natto, Anura Ariyawardana, Lina M. Mejia, Milda Chmieliauskaite, Craig S. Miller, Mark Ingram, et al.

    Objectives: To assess the effectiveness of topical interventions in the management of burning mouth syndrome (BMS), based on the core outcome domains recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT).Methods: A systematic literature review of RCTs on topical interventions for the management of BMS, published in PubMed, Web of Science, PsycInfo, Cochrane Database/Central, and Google Scholar through May 2021 was performed.Results: Eight RCTs (n = 358 study participants) were included in this study. Due to underreporting of IMMPACT domains, publication bias, high degree of heterogeneity between studies, meta‐analysis was not undertaken. Based on changes in visual analogue pain scores (ΔVAS), the most reported outcome, the effectiveness of the topical interventions was demonstrated; however, it is low level of evidence.Conclusions: High levels of variability (interventions, outcomes, outcome measurement tools, and intervention effects evaluated), heterogeneity, publication bias, and underreporting of IMMPACT domains were observed across the RCTs. This systematic review highlights the need for application of standardized outcome measures to future RCTs. At the present time, there is lack of moderate‐strong evidence on short‐ and long‐term outcomes to support or refute the use of any particular topical intervention in managing BMS. Future RCTs with standardized outcome measures are needed.


  • Reply to Currie et al.

    by Milda Chmieliauskaite, Elisabeth A. Stelson, Joel B. Epstein, Gary D. Klasser, Arwa Farag, Barbara Carey, Rui Albuquerque, Lina Mejia, Anura Ariyawardana, Cibele Nasri-Heir, et al.

  • Open Access

    Correction to: IMMPACT-recommended outcome measures and tools of assessment in burning mouth syndrome RCTs: an international Delphi survey protocol

    by Barbara Carey, Arwa M. Farag, Cibele Nasri-Heir, Gary D. Klasser, Anura Ariyawardana, Milda Chmieliauskaite, Andrea Sardella, Charles R. Carlson, Craig S. Miller, Lina Mejia, et al.

    An amendment to this paper has been published and can be accessed via the original article.

  • Is burning mouth a syndrome or a disorder? A commentary

    by Craig S. Miller, Arwa M. Farag, Milda Chmieliauskaite, Anura Ariyawardana, Rui Albuquerque, Charles R. Carlson, Heli Forssell, Gary D. Klasser, Cibele Nasri-Heir, Michele D. Mignogna, et al.


  • Open Access

    Radiographic Diagnosis of a Central Giant Cell Granuloma Using Advanced Imaging: Cone Beam Computed Tomography

    by Ahmed Z. Abdelkarim, Shaimaa M. Abu el Sadat, Milda Chmieliauskaite, Ali Syed

    Central giant cell granuloma (CGCG) is a benign non-neoplastic, proliferative intraosseous lesion of the jaw with an unknown etiology often diagnosed during the first two decades of life. The true nature of this lesion is controversial and remains elusive. Here, we report a case of central giant cell granuloma, diagnosed using cone-beam computed tomography (CBCT). A 21-year-old female presented to the clinic complaining of a painless swelling involving the right side of the mandible that had started one year previously. A CBCT scan revealed a well-defined, multilocular radiolucent lesion on the right side of the mandible extending from the molar region to the ramus with wispy septations. Wispy septations and undulating borders are some of the characteristic radiographic features of a central giant cell granuloma. The patient underwent an excisional biopsy. The biopsy revealed multinucleated giant cells in a fibrous stroma confirming our radiographic diagnosis of a central giant cell lesion.


  • Clinician Perspectives of Internet-Based Information on Burning Mouth Syndrome

    by Milda Chmieliauskaite, Emily Kim, Eric T. Stoopler, Thomas P. Sollecito

  • An Intraoral Mass Associated With Myelodysplastic Syndrome

    by James K. Mangan, Milda Chmieliauskaite, Eric T. Stoopler

    A man in his 70s with hypertension, benign prostatic hypertrophy, and myelodysplastic syndrome (MDS) presented for a second opinion regarding treatment of MDS. Three years prior he had developed neutropenia and mild thrombocytopenia. A bone marrow biopsy sample demonstrated refractory cytopenia with multilineage dysplasia. Cytogenetic testing results were normal, and there were 5% bone marrow blasts. The patient was treated initially with cyanocobalamin 250 micrograms daily, then danazol 200 milligrams 3 times daily, then epoietin α 60,000 units weekly. Filgrastim 300 micrograms weekly was added to epoietin α to attempt to augment response after 1 year of therapy. After approximately 2 years, he developed more pronounced cytopenias and presented with a white blood cell count of 2100/μL(480 neutrophils), hemoglobin level of 8.4 g/dL, and platelet count of 92 000/μL. He noted fatigue, but otherwise felt well. Physical examination revealed an isolated, symptomatic polypoid mass involving his right upper labial mucosa (Figure). It had been recently biopsied without definitive diagnosis, but since the biopsy, the mass had increased in size.